Izrael - hebrejština - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.

Izrael - hebrejština - Ministry of Health

abic marketing ltd, israel - ibuprofen - תרחיף - ibuprofen 20 mg/ml - ibuprofen

Izrael - hebrejština - Ministry of Health

dexcel ltd, israel - ranitidine as hydrochloride - טבליה - ranitidine as hydrochloride 150 mg - ranitidine - ranitidine - for the treatment of duodenal ulcer, benign gastric ulcer, oesophageal reflux disease and ulcers associated with the use of non-steroidal anti-inflammatory agents. for the prophylaxis of haemorrhage from stress ulceration.

Izrael - hebrejština - Ministry of Health

dexcel ltd, israel - ranitidine as hydrochloride - קפליות - ranitidine as hydrochloride 300 mg - ranitidine - ranitidine - treatment of duodenal ulcer and beingn gastric ulcer, esophageal reflux disease, peptic ulcers associated with the use of non-steroidal anti-inflammatory agent (nsaids). prophylaxis of gastrointestinal hemorrhage from stress ulceration.

Izrael - hebrejština - Ministry of Health

takeda israel ltd - pantoprazole - טבליה - pantoprazole 20 mg - pantoprazole - pantoprazole - treatment of reflux oesophagitis and associated symptoms (e.g. hearburn acid regurgitation pain on swallowing) . for long-term management and prevention of relapse in reflux oesophagitis. prevention of gastroduodenal ulcers induced by non-steroidal anti-inflammatory drugs (nsaids) in patients at risk with a need for continuous nsaids treatment.

Izrael - hebrejština - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Izrael - hebrejština - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.

Izrael - hebrejština - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Izrael - hebrejština - Ministry of Health

novartis israel ltd - hydrochlorothiazide; valsartan - טבליות מצופות פילם - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.

Izrael - hebrejština - Ministry of Health

tzamal bio-pharma ltd - methotrexate - תמיסה להזרקה - methotrexate 50 mg/ml - methotrexate - methotrexate - psoriasis in adult patients :because of the high risk attending its use, methotrexate is indicated only in the symptomatic control of severe recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, and only when the diagnosis has been established, as by biopsy and/or after dermatological consultation. rheumatoid arthritis: methotrexate can be used in the treatment of selected adults with severe rheumatoid arthritis, only when the diagnosis has been well estabished according to rheumatological standards, with inadequate response to other forms of antirheumatic therapy, including full dose nsaids and usually a trial of at least one or more disease-modifying antirheumatic drugs.juvenile idiopathic arthritis:treatment of polyarthritic forms of severe, active juvenile idiopathic arthritis in patients 3 years of age and above when the response to non-steroidal anti-inflammatory drugs (nsaids) has been inadequate